Bacterial cupredoxin azurin hijacks cellular signaling networks: Protein-protein interactions and cancer therapy

Bacterial Carriers for Glioblastoma Therapy

(2017) Nalini Mehta et al.   Molecular Therapy-Oncolytics

p28-Mediated Activation of p53 in G 2 –M Phase of the Cell Cycle Enhances the Efficacy of DNA Damaging and Antimitotic Chemotherapy

(2016) Tohru Yamada et al.   CANCER RESEARCH

Modulation of membrane properties of lung cancer cells by azurin enhances the sensitivity to EGFR-targeted therapy and decreased β1 integrin-mediated adhesion

(2016) Nuno Bernardes et al.   CELL CYCLE

p53 Proteoforms and Intrinsic Disorder: An Illustration of the Protein Structure–Function Continuum Concept

(2016) Vladimir Uversky   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study

(2016) Rishi R. Lulla et al.   NEURO-ONCOLOGY

Discovery of Azurin-Like Anticancer Bacteriocins from Human Gut Microbiome through Homology Modeling and Molecular Docking against the Tumor Suppressor p53

(2016) Chuong Nguyen et al.   Biomed Research International

Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances

(2015) Mohammad Hojjat-Farsangi   JOURNAL OF DRUG TARGETING

Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells

(2014) Elzbieta Gocek et al.   CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES

Bacterial proteins and peptides in cancer therapy

(2014) Ananda M Chakrabarty et al.   Bioengineered

A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours

(2013) M A Warso et al.   BRITISH JOURNAL OF CANCER

p28, A first in class peptide inhibitor of cop1 binding to p53

(2013) T Yamada et al.   BRITISH JOURNAL OF CANCER

p28, an Anionic Cell-Penetrating Peptide, Increases the Activity of Wild Type and Mutated p53 without Altering Its Conformation

(2013) Tohru Yamada et al.   MOLECULAR PHARMACEUTICS

The Bacterial Protein Azurin Impairs Invasion and FAK/Src Signaling in P-Cadherin-Overexpressing Breast Cancer Cell Models

(2013) Nuno Bernardes et al.   PLoS One

Escherichia coli Nissle 1917 Targets and Restrains Mouse B16 Melanoma and 4T1 Breast Tumors through Expression of Azurin Protein

(2012) Yunlei Zhang et al.   APPLIED AND ENVIRONMENTAL MICROBIOLOGY

Eph receptors and ephrins as targets for cancer therapy

(2012) Hong-Qing Xi et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt

(2011) Rajeshwari R. Mehta et al.   ANGIOGENESIS

Induction of apoptosis of azurin synthesized from P. aeruginosa MTCC 2453 against Dalton's lymphoma ascites model

(2011) Sankar Ramachandran et al.   BIOMEDICINE & PHARMACOTHERAPY

Does azurin bind to the transactivation domain of p53? A Trp phosphorescence study

(2011) Edi Gabellieri et al.   BIOPHYSICAL CHEMISTRY

Interaction of an anticancer peptide fragment of azurin with p53 and its isolated domains studied by atomic force spectroscopy

(2011) Anna Rita Bizzarri et al.   International Journal of Nanomedicine

Small Azurin Derived Peptide Targets Ephrin Receptors for Radiotherapy

(2011) Ewa D. Micewicz et al.   International Journal of Peptide Research and Therapeutics

Azurin modulates the association of Mdm2 with p53: SPR evidence from interaction of the full-length proteins

(2011) Fabio Domenici et al.   JOURNAL OF MOLECULAR RECOGNITION

Recent Patents on Live Bacteria and their Products as Potential Anticancer Agents

(2011) Arsenio M. Fialho et al.   Recent Patents on Anti-Cancer Drug Discovery

The Bacterial Protein Azurin Enhances Sensitivity of Oral Squamous Carcinoma Cells to Anticancer Drugs

(2011) Jeong-Hae Choi et al.   YONSEI MEDICAL JOURNAL

The interaction of azurin and C-terminal domain of p53 is mediated by nucleic acids

(2010) Chao Xu et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination

(2010) Lee Jia et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Structural characteristics of the hydrophobic patch of azurin and its interaction with p53: a site-directed spin labeling study

(2010) Chao Xu et al.   Science China-Life Sciences

Noncationic Peptides Obtained From Azurin Preferentially Enter Cancer Cells

(2009) B. N. Taylor et al.   CANCER RESEARCH

Modeling the interaction between the N-terminal domain of the tumor suppressor p53 and azurin

(2009) Monia Taranta et al.   JOURNAL OF MOLECULAR RECOGNITION

A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells

(2009) T. Yamada et al.   MOLECULAR CANCER THERAPEUTICS

Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells

(2009) A S Ribeiro et al.   ONCOGENE

Structural Biology of the Tumor Suppressor p53

(2008) Andreas C. Joerger et al.   Annual Review of Biochemistry

Probing the interaction between p53 and the bacterial protein azurin by single molecule force spectroscopy

(2008) Monia Taranta et al.   JOURNAL OF MOLECULAR RECOGNITION

Bacterial targeted tumour therapy-dawn of a new era

(2007) Ming Q Wei et al.   CANCER LETTERS